Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.45

-2.7%

Jan 8 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (6824)	7/30/2002 3:03:27 PM
From: Czechsinthemail	of 52153

The likelihood of landing a position elsewhere with a more lucrative options package is certainly a possibility if Rubin decided to leave. Hunkering down and cost-cutting in SEPR's R&D program would be a possibility if the company was urging him out. As far as the stock price is concerned, it looks like a major overreaction. Perhaps it is a "perfect storm" effect: having the Rubin news appear on a day when the WSJ has an article raising fears about biotech financing coupled with selling momentum driven by a falling stock price. To the extent that we've seen is largely a bear raid, the stock may rebound sharply on short-covering and bargain buying.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next